China NMPA Drug Inspection - Guizhou Bailing Enterprise Group Zhengxin Pharmaceutical Co., Ltd. - Norfloxacin capsules
China NMPA drug inspection for Guizhou Bailing Enterprise Group Zhengxin Pharmaceutical Co., Ltd. published September 21, 2019. Drug: Norfloxacin capsules. The Henan Provincial Drug Administration issued an announcement on September 21, 2019, detailing findings of seven batch
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Guizhou Bailing Enterprise Group Zhengxin Pharmaceutical Co., Ltd. published September 21, 2019. Drug: Norfloxacin capsules. The Henan Provincial Drug Administration issued an announcement on September 21, 2019, detailing findings of seven batch
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox